Metaraminol
- US DailyMed: Metaraminol
category
- AU: C
administration
- C01CA09 (WHO)
- (1R,2S)-3-[-2-amino-1-hydroxy-propyl]phenol
- 54-49-9 Y
33402-03-8 (bitartrate)
- 5906
- 7229
- DB00610 Y
- 5695 Y
- 818U2PZ2EH
- D08192 Y
- CHEBI:6794 Y
- ChEMBL1201319 N
- DTXSID8023268
- Interactive image
- O[C@H](c1cc(O)ccc1)[C@@H](N)C
- InChI=1S/C9H13NO2/c1-6(10)9(12)7-3-2-4-8(11)5-7/h2-6,9,11-12H,10H2,1H3/t6-,9-/m0/s1 Y
- Key:WXFIGDLSSYIKKV-RCOVLWMOSA-N Y
Metaraminol, previously sold under the brand name Aramine among others and also known as metaradrine, is a stereoisomer of meta-hydroxynorephedrine (3,β-dihydroxyamphetamine), is a potent sympathomimetic amine used in the prevention and treatment of hypotension, particularly as a complication of anesthesia. It is an α1-adrenergic receptor agonist with some β-adrenergic effect.[2] It is currently sold in its generic form by Slayback Pharma.[3]
Pharmacology and use as a vasopressor
Metaraminol is given intravenously as either a bolus (often 0.5–1 mg doses) or as an infusion, usually via peripheral intravenous access. Metaraminol is commonly available as 10 mg in 1 mL, that requires dilution prior to administration (often made up to a 0.5 mg/mL solution), however pre-prepared syringes of metaraminol for bolus use for hypotension are also commonly available.[4][5]
Pharmacodynamics
The dominant mechanism for the vasopressor action of metaraminol is indirect,[6] with metaraminol displacing noradrenaline from neuronal vesicles in order for the noradrenaline to exert its vasopressor action.[7] Metaraminol at higher doses may have direct alpha-adrenergic agonist and β1 adrenergic agonist effects.[6] However at doses common in clinical practice, the indirect α1 adrenergic effects predominate, such that reflex bradycardia is a common side-effect.
Research
Metaraminol is also used in the treatment of priapism.[8][9][10]
References
- ^ "Injection : Aramine (Metaraminol Bitartrate)" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 12 March 2022.
- ^ Kee VR (August 2003). "Hemodynamic pharmacology of intravenous vasopressors". Crit Care Nurse. 23 (4): 79–82. doi:10.4037/ccn2003.23.4.79. PMID 12961786.
- ^ "ANDA Approval for Metaraminol" (PDF). United States Food and Drug Administration. 24 August 2021. Retrieved 13 August 2022.
- ^ "Metaraminol 0.5 mg/ml, Solution for Injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Retrieved 19 October 2022.
- ^ Goodrick N, Wentrup T, Messer G, Gleeson P, Culwick M, Goulding G (21 August 2020). "Pre-filled emergency drugs: The introduction of pre-filled metaraminol and ephedrine syringes into the main operating theatres of a major metropolitan centre". Australasian Anaesthesia (2013): 127–134.
- ^ a b "Metaraminol". Deranged Physiology. Retrieved 19 October 2022.
- ^ Harrison DC, Chidsey CA, Braunwald E (September 1963). "Studies on the Mechanism of Action of Metaraminol (Aramine)". Annals of Internal Medicine. 59 (3): 297–305. doi:10.7326/0003-4819-59-3-297. PMID 14065947.
- ^ McDonald M, Santucci R (2004). "Successful management of stuttering priapism using home self-injections of the alpha-agonist metaraminol". Int Braz J Urol. 30 (2): 121–2. doi:10.1590/S1677-55382004000200007. PMID 15703094.
- ^ Koga S, Shiraishi K, Saito Y (1990). "Post-traumatic priapism treated with metaraminol bitartrate: case report". J Trauma. 30 (12): 1591–3. doi:10.1097/00005373-199012000-00029. PMID 2258979.
- ^ Block T, Sturm W, Ernst G, Staehler G, Schmiedt E (1988). "[Metaraminol in therapy of various forms of priapism]". Urologe A. 27 (4): 225–9. PMID 3140463.
External links
- "Metaraminol". Drug Information Portal. U.S. National Library of Medicine.
- "Metaraminol bitartrate". Drug Information Portal. U.S. National Library of Medicine.
- v
- t
- e
dopaminergic agents
Adrenergic agonists |
| ||||||
---|---|---|---|---|---|---|---|
Dopamine agonists | |||||||
Both | |||||||
Unknown/ungrouped |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e